Skip to content

Study · Randomized controlled trial · n = 90 · 2018

11 results

The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial.

Elbarbary NS, Ismail EAR, El-Naggar AR, Hamouda MH, El-Hamamsy M

Pediatric diabetes26 Jul 2017Cited by 68 (Europe PMC)

PMID28744992 (opens in a new tab)DOI10.1111/pedi.12564 (opens in a new tab)PepBankPUB-28744992
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced HbA1c versus placebo.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced HbA1c compared with placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseHbA1c
    Study

    n = 90

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    HbA1c
    8.2%
    baseline
    HbA1c
    7.4%
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced urinary albumin excretion versus placebo.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced urinary albumin excretion compared with placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseUrinary albumin excretion
    Study

    n = 90

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    UAE
    91.7 mg/g creatinine
    baseline
    UAE
    38.5 mg/g creatinine
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced A1M versus placebo.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced A1M compared with placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseAlpha 1-microglobulin
    Study

    n = 90

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    A1M
    16.5 mg/L
    baseline
    A1M
    9.3 mg/L
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced MDA versus placebo.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced MDA compared with placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseMalondialdehyde
    Study

    n = 90

    Comparator
    placebo
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    MDA
    25.5 nmol/mL
    baseline
    MDA
    18.2 nmol/mL
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly increased TAC versus placebo.

    In plain wordsIn children with diabetic nephropathy, carnosine increased TAC compared with placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseTotal antioxidant capacity
    Study

    n = 90

    Comparator
    placebo
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced HbA1c compared with baseline.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced HbA1c compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseHbA1c versus baseline
    Study

    n = 45

    Comparator
    baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    HbA1c
    8.2%
    baseline
    HbA1c
    7.4%
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced urinary albumin excretion compared with baseline.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced urine albumin compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseUrinary albumin excretion versus baseline
    Study

    n = 45

    Comparator
    baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    UAE
    91.7 mg/g creatinine
    baseline
    UAE
    38.5 mg/g creatinine
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced A1M compared with baseline.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced A1M compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseAlpha 1-microglobulin versus baseline
    Study

    n = 45

    Comparator
    baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    A1M
    16.5 mg/L
    baseline
    A1M
    9.3 mg/L
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly reduced MDA compared with baseline.

    In plain wordsIn children with diabetic nephropathy, carnosine reduced MDA compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseMalondialdehyde versus baseline
    Study

    n = 45

    Comparator
    baseline
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    MDA
    25.5 nmol/mL
    baseline
    MDA
    18.2 nmol/mL
    after treatment

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In pediatric diabetic nephropathy, carnosine significantly increased TAC compared with baseline.

    In plain wordsIn children with diabetic nephropathy, carnosine increased antioxidant capacity compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseTotal antioxidant capacity versus baseline
    Study

    n = 45

    Comparator
    baseline
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks, carnosine treatment resulted in significant decrease of HbA1c (8.2 ± 2.1% vs 7.4 ± 1.3%), UAE (91.7 vs 38.5 mg/g creatinine), A1M (16.5 ± 6.8 mg/L vs 9.3 ± 6.6 mg/L), MDA levels (25.5 ± 8.1 vs 18.2 ± 7.7 nmol/mL) while TAC levels were increased compared with baseline levels (P < .001…
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.
  11. 11HumanRandomized controlled trialSafety outcome

    No adverse reactions due to carnosine supplementation were reported in pediatric diabetic nephropathy.

    In plain wordsIn children with diabetic nephropathy, the study reported no adverse reactions due to carnosine.

    Peptide
    L-carnosine
    Outcome
    Not applicableAdverse reactions
    Study

    n = 45

    Outcome group
    Adverse events · Whole body
    Studied dose
    1 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions due to carnosine supplementation were reported.
    2 context sentences
    Summary · context
    This randomized placebo-controlled trial included 90 patients with diabetic nephropathy, despite oral angiotensin-converting enzyme inhibitors (ACE-Is), who were randomly assigned to receive either 12 weeks of carnosine 1 g/day (n = 45), or matching placebo (n = 45).
    Summary · context
    Oral supplementation with L-Carnosine for 12 weeks resulted in a significant improvement of oxidative stress, glycemic control and renal function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.